This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Welcome to Novo Nordisk Rare Diseases Science Hub


The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a non-US healthcare professional.

Reference not found.
Reference not found.


Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome. Lancet. 2013;381(9863):333–342.


Horikawa R, Ogata T, Matsubara Y, et al. Long-term efficacy and safety of two doses of Norditropin(®) (somatropin) in Noonan syndrome: a 4-year randomized, double-blind, multicenter trial in Japanese patients. Endocr J. 2020;67(8):803–818.


Rohrer TR, Abuzzahab J, Backeljauw P, et al. Long-Term Effectiveness and Safety of Childhood Growth Hormone Treatment in Noonan Syndrome. Horm Res Paediatr. 2020;93(6):380–395.


Novo Nordisk. Norditropin (somatropin). Summary of Product Characteristics. June 2021. In.


Novo Nordisk. Norditropin (somatropin). Summary of Product Characteristics. June 2021. In.


Limal JM, Parfait B, Cabrol S, et al. Noonan syndrome: relationships between genotype, growth, and growth factors. J Clin Endocrinol Metab. 2006;91(1):300–306.


MacFarlane CE, Brown DC, Johnston LB, et al. Growth hormone therapy and growth in children with Noonan's syndrome: results of 3 years' follow-up. J Clin Endocrinol Metab. 2001;86(5):1953–1956.


Malaquias AC, Noronha RM, Souza TTO, et al. Impact of Growth Hormone Therapy on Adult Height in Patients with PTPN11 Mutations Related to Noonan Syndrome. Horm Res Paediatr. 2019;91(4):252–261.


Noordam C, Draaisma JM, van den Nieuwenhof J, van der Burgt I, Otten BJ, Daniels O. Effects of growth hormone treatment on left ventricular dimensions in children with Noonan's syndrome. Horm Res. 2001;56(3-4):110–113.


Noordam C, Peer PG, Francois I, De Schepper J, van den Burgt I, Otten BJ. Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11. Eur J Endocrinol. 2008;159(3):203–208.


Osio D, Dahlgren J, Wikland KA, Westphal O. Improved final height with long-term growth hormone treatment in Noonan syndrome. Acta Paediatr. 2005;94(9):1232–1237.


Ozono K, Ogata T, Horikawa R, et al. Efficacy and safety of two doses of Norditropin(®) (somatropin) in short stature due to Noonan syndrome: a 2-year randomized, double-blind, multicenter trial in Japanese patients. Endocr J. 2018;65(2):159–174.


Ranke MB, Lindberg A, Carlsson M, Camacho-Hübner C, Rooman R. Treatment with Growth Hormone in Noonan Syndrome Observed during 25 Years of KIGS: Near Adult Height and Outcome Prediction. Horm Res Paediatr. 2019;91(1):46–55.


Romano AA, Dana K, Bakker B, et al. Growth response, near-adult height, and patterns of growth and puberty in patients with noonan syndrome treated with growth hormone. J Clin Endocrinol Metab. 2009;94(7):2338–2344.


Tamburrino F, Gibertoni D, Rossi C, et al. Response to long-term growth hormone therapy in patients affected by RASopathies and growth hormone deficiency: Patterns of growth, puberty and final height data. Am J Med Genet A. 2015;167a(11):2786–2794.


Romano A, Kaski JP, Dahlgren J, Kelepouris N, Pietropoli A, Rohrer TR, Polak M. Cardiovascular safety of growth hormone treatment in Noonan syndrome: real-world evidence. Endocrine Connections. 2021; Published online ahead of print, EC-21-0549.


Höybye C, Sävendahl L, Christesen HT, et al. The NordiNet® International Outcome Study and NovoNet® ANSWER Program®: rationale, design, and methodology of two international pharmacoepidemiological registry-based studies monitoring long-term clinical and safety outcomes of growth hormone therapy (Norditropin®). Clin Epidemiol. 2013;5:119–127.


Marino B, Digilio MC, Toscano A, Giannotti A, Dallapiccola B. Congenital heart diseases in children with Noonan syndrome: An expanded cardiac spectrum with high prevalence of atrioventricular canal. J Pediatr. 1999;135(6):703–706.